Kowa Submits NDA For Peretinoin To Reduce HCC Recurrence Risk
This article was originally published in PharmAsia News
Nagoya-based Kowa has submitted a new drug application for a novel synthetic retinoid, peretinoin (NIK-333) to prevent the recurrence of liver cancer after surgical resection of primary tumors
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.